A cascade-responsive nanoplatform for cyclooxygenase-2 inhibition and inflammation regulation to enhance photoimmunotherapy
Source abstract
Abstract
Photodynamic immunotherapy (PIT) has emerged as a promising cancer treatment by photo-activating host immune system to eliminate tumor. However, excessive oxidative stress generated during PIT often induces uncontrolled inflammatory responses and activates immunosuppressive pathways to determine the efficacy of PIT. Herein, we developed a cascade responsive nanoplatform (FBC@PTI) to reduce the inflammation level by co-assembly of an indomethacin-based amphiphilic block copolymer and photosensitizer tetrafluorophenyl bacterial chlorophyll (FBC). Under acidic TME conditions, FBC@PTI underwent surface charge reversal to facilitate tumor penetration and cell internalization. Upon 750 nm light irradiation, FBC could not only generate robust reactive oxygen species (ROS) to induce immunogenic cell death (ICD), but also trigger the disassociation of FBC@PTI to release indomethacin, and inhibit cyclooxygenase-2 (COX-2) to reduce inflammatory level. In vivo experiments demonstrated that the released indomethacin can effectively suppress the expression level of COX-2 (61.1%) and PGE₂ (66.5%), and then reduce the inflammatory factor level of TNF-α (25.8%) and IL-6 (74.0%) from macrophages. As a result, immune activity could further elevate to enhance CD4⁺ and CD8⁺ T cell infiltration and reduce Treg accumulation under controllable inflammatory level. This strategy of regulating inflammation in PIT would offer a potential path for improving the efficacy of PIT. STATEMENT OF SIGNIFICANCE: We developed a cascade responsive nanoplatform (FBC@PTI) that integrates photoimmunotherapy with programmable inflammation modulation. Enabled by pH-triggered charge reversal and light-induced ROS generation, this system enhances tumor-targeted delivery, induces immunogenic cell death, and simultaneously releases indomethacin to inhibit COX-2-mediated inflammatory signaling. By coordinating immune activation with precise inflammation regulation, this strategy offers a promising approach to improve the therapeutic efficacy of photoimmunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. A guide to cancer immunotherapy: from T cell basic science to clinical practice10.1038/s41577-020-0306-5 ↗
2. A review of cancer immunotherapy: from the past, to the present, to the future10.3747/co.27.5223 ↗
3. A comprehensive review of immune checkpoint inhibitors for cancer treatment
4. Immune-checkpoint inhibitors: long-term implications of toxicity10.1038/s41571-022-00600-w ↗
5. MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy10.1038/s41417-025-00886-9 ↗
6. Cancer mRNA vaccines: clinical advances and future opportunities10.1038/s41571-024-00902-1 ↗
7. Cancer vaccines as enablers of immunotherapy10.1038/s41590-025-02308-2 ↗
8. Cancer vaccines: current status and future directions10.1186/s13045-025-01670-w ↗
9. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors10.1038/s41423-024-01207-0 ↗
10. Engineering innate immune cells for cancer immunotherapy10.1038/s41587-025-02629-5 ↗
11. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma10.1186/s40425-015-0067-z ↗
12. Long-term survival by number of immune checkpoint inhibitors in PD-L1-negative metastatic NSCLC: a systematic review and meta-analysis10.1001/jamanetworkopen.2024.57357 ↗
13. Inducing immunogenic cancer cell death through oxygen-economized photodynamic therapy with nitric oxide-releasing photosensitizers
14. Innate immune activation with multifunctional nanoparticles for cancer immunotherapy
15. Synergistic cancer photoimmunotherapy by harnessing near-infrared-activated nanoparticles containing charge transfer complexes10.1002/anie.202423550 ↗
16. Near Infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy10.3390/ijms24032655 ↗
17. Near-infrared photoimmunotherapy of cancer10.1021/acs.accounts.9b00273 ↗
18. Hypoxia-responsive golgi-targeted prodrug assembled with anthracycline for improved antitumor and antimetastasis efficacy10.1021/acsnano.3c07183 ↗
19. A one stone three birds paradigm of photon-driven pyroptosis dye for amplifying tumor immunotherapy
20. An all-in-one PEGylated NIR-II conjugated polymer for high-resolution blood circulation imaging and photothermal immunotherapy10.1016/j.biomaterials.2025.123107 ↗
21. Near-infrared heptamethine cyanine photosensitizers with efficient singlet oxygen generation for anticancer photodynamic therapy10.1002/anie.202484761 ↗
22. Self-assembled peptide-derived proteolysis-targeting Chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy10.1002/anie.202414146 ↗
23. Tumor homing chimeric peptide rhomboids to improve photodynamic performance by inhibiting therapy-upregulated cyclooxygenase-2
24. Smoldering and polarized inflammation in the initiation and promotion of malignant disease10.1016/j.ccr.2005.02.013 ↗
25. Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment10.1016/j.biomaterials.2024.122954 ↗
26. PGE2 induced in and released by dying cells functions as an inhibitory DAMP10.1073/pnas.1602023113 ↗
27. A self-delivery nanodrug simultaneously inhibits COX-2/PGE2 mediated inflammation and downregulates PD-L1 to boost photoimmunotherapy
28. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase10.3390/ijms23031432 ↗
29. Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy10.1016/j.biomaterials.2024.122695 ↗
30. A poly-prodrug nanosphere for modulating janus-faced nature of pyroptosis to launch an immune offensive and defensive warfare reigniting the cancer-immunity cycle
31. Glycosylated AIE-active red light-triggered photocage with precisely tumor targeting capability for synergistic type I photodynamic therapy and CPT Chemotherapy
32. Near-infrared light-responsive immunomodulator prodrugs rejuvenating immune microenvironment for "cold" tumor photoimmunotherapy10.1002/anie.202425309 ↗
33. Magnetic induction heating enables on-demand drug release via diels–Alder polymeric nanocarriers10.1021/acs.biomac.5c00321 ↗
34. Ultrasound-activated sonophage synergizes sonodynamic therapy and saltoptosis for solid tumor eradication
35. Ultrasound-responsive lipid nanosonosensitizers with size reduction and NO release: synergistic sonodynamic-chemo-immunotherapy for pancreatic tumors10.1002/anie.202507388 ↗
36. A near-infrared bacteriochlorin nanomedicine for enhanced photodynamic therapy10.1016/j.eurpolymj.2023.112328 ↗
37. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway
38. Aminopeptidase N-responsive conjugates with tunable charge-reversal properties for highly efficient tumor accumulation and penetration
39. A TME-enlightened protein-binding photodynamic nanoinhibitor for highly effective oncology treatment10.1073/pnas.2321545121 ↗
40. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
41. Immunogenic cell death and metabolic reprogramming in cancer: mechanisms, synergies, and innovative therapeutic strategies10.3390/biomedicines13040950 ↗
42. Augmenting cancer therapy with a supramolecular immunogenic cell death inducer: a lysosome-targeted NIR-light-activated ruthenium(II) metallacycle10.1021/jacs.3c13224 ↗
43. Recent advances in targeting COX-2 for cancer therapy: a review10.1039/D5MD00196J ↗
44. NOS2 and COX-2 Co-expression promotes cancer progression: a potential target for developing agents to prevent or treat highly aggressive breast cancer10.3390/ijms25116103 ↗
45. Single-component dual-functional autoboost strategy by dual photodynamic and cyclooxygenase-2 inhibition for lung cancer and spinal metastasis10.4028/b-wjQRP6 ↗
46. Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy
47. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy10.1186/s13046-025-03377-9 ↗
48. Celecoxib in oncology: targeting the COX-2/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy10.3389/fphar.2025.1691392 ↗
49. Breaking immune evasion in breast cancer by targeting COX-2/PGE2 pathway10.1016/j.mce.2025.112617 ↗
50. Cancer-related inflammation10.1038/nature07205 ↗
51. Photodynamic therapy-induced inflammation and adverse effects: an updated review
52. Role of cytokines in photodynamic therapy-induced local and systemic inflammation10.1038/sj.bjc.6600864 ↗
53. Leveraging immunogenic cell death to enhance the immune response against malignant pleural mesothelioma tumors10.1021/jacs.4c17966 ↗
54. Targeting immunogenic cell stress and death for cancer therapy10.1038/s41573-024-00920-9 ↗
55. Tumor-associated macrophages as major players in the tumor microenvironment10.3390/cancers6031670 ↗
56. Macrophage-derived exosomes in cancer: a double-edged sword with therapeutic potential10.1186/s12951-025-03321-1 ↗
57. NIR-II imaging-guided self-enhanced nanomedicine with reactive oxygen species amplification for type I photodynamic therapy of prostate cancer
58. NIR-triggered multifunctional and degradable nanoplatform based on an ROS-sensitive block copolymer for imaging-guided chemo-phototherapy10.1021/acs.biomac.9b01123 ↗
59. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery10.3892/ijo.2016.3421 ↗
60. Smoldering and polarized inflammation in the initiation and promotion of malignant disease10.1016/j.ccr.2005.02.013 ↗